Limits...
Elevation of the Serum Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 in Coronary Artery Disease.

Jin SA, Seo HJ, Kim SK, Lee YR, Choi S, Ahn KT, Kim JH, Park JH, Lee JH, Choi SW, Seong IW, Jeon BH, Jeong JO - Korean Circ J (2015)

Bottom Line: Also, they revealed a negative correlation with ejection fraction (EF, r=-0.221; p=0.002).However, there were no significant differences among the three groups, were divided by their levels of APE1/Ref-1, for major adverse cardiovascular events (death, recurrent MI, stroke, revascularization) (8.2 vs. 14.0 vs. 12.5%, p=ns).They are correlated with Troponin I, NT-proBNP, and EF.

View Article: PubMed Central - PubMed

Affiliation: Divison of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.

ABSTRACT

Background and objectives: Apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1/Ref-1) is a multifunctional protein involved in the DNA base excision repair pathway, inflammation, angiogenesis, and survival pathways. We investigated serum APE1/Ref-1 in patients with coronary artery disease (CAD).

Subjects and methods: Serum APE1/Ref-1 was measured with a sandwich enzyme-linked immunosorbent assay from 360 patients who received coronary angiograms. They were divided into two groups; a control (n=57) and a CAD group (n=303), the latter included angina (n=128) and myocardial infarction (MI, n=175).

Results: The levels of APE1/Ref-1 were higher in the CAD than the control (0.63±0.07 vs. 0.12±0.07 ng/100 µL, respectively; p<0.01). They were also higher in MI than angina (0.81±0.10 vs. 0.38±0.11 ng/100 µL, respectively; p<0.01) and different according to the thrombolysis in myocardial infarction (TIMI) flow (0.88±0.09 for TIMI flow 0, 1, 2 vs. 0.45±0.13 ng/100 µL for TIMI flow 3, p<0.01) in acute coronary syndrome. In correlation analysis, the levels of APE1/Ref-1 were positively correlated with Troponin I (r=0.222; p<0.0001) and N-terminal pro-B type natriuretic peptide (NT-proBNP, r=0.217; p<0.0001) but not high sensitivity to C-reactive protein. Also, they revealed a negative correlation with ejection fraction (EF, r=-0.221; p=0.002). However, there were no significant differences among the three groups, were divided by their levels of APE1/Ref-1, for major adverse cardiovascular events (death, recurrent MI, stroke, revascularization) (8.2 vs. 14.0 vs. 12.5%, p=ns).

Conclusion: The levels of serum APE1/Ref-1 are elevated in CAD, and are higher in MI than in angina. They are correlated with Troponin I, NT-proBNP, and EF.

No MeSH data available.


Related in: MedlinePlus

Serum APE1/Ref-1 in coronary artery disease. Serum APE1/Ref-1 was assayed by ELISA. Each bar shows the mean±standard error of the mean. A. The levels of serum APE1/Ref-1 are higher in patients with myocardial infarction (MI) than angina. *p<0.01, control vs. angina and angina vs. MI, **p<0.001, control vs. MI. B. Serum APE1/Ref-1 is not significantly different between the non-ST elevation myocardial infarction (NSTEMI) and STEMI patients. *p<0.01, ns; non-specific. C. Serum APE1/Ref-1 levels are associated with thrombolysis in myocardial infarction (TIMI) grade flow in acute coronary syndrome (ACS). TIMI flow 0-2 shows higher levels of APE1/Ref-1 than TIMI 3. *p<0.01, TIMI 3 vs. TIMI 0-2. D. The elevated APE1/Ref-1 decreased 4 days after CAG from 1.62±0.27 ng/100 µL to 0.35±0.23 ng/100 µL. *p<0.01. APE1/Ref-1: apurinic/apyrimidinic endonuclease 1/redox effector factor 1, CAG: coronary angiograms.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4580694&req=5

Figure 2: Serum APE1/Ref-1 in coronary artery disease. Serum APE1/Ref-1 was assayed by ELISA. Each bar shows the mean±standard error of the mean. A. The levels of serum APE1/Ref-1 are higher in patients with myocardial infarction (MI) than angina. *p<0.01, control vs. angina and angina vs. MI, **p<0.001, control vs. MI. B. Serum APE1/Ref-1 is not significantly different between the non-ST elevation myocardial infarction (NSTEMI) and STEMI patients. *p<0.01, ns; non-specific. C. Serum APE1/Ref-1 levels are associated with thrombolysis in myocardial infarction (TIMI) grade flow in acute coronary syndrome (ACS). TIMI flow 0-2 shows higher levels of APE1/Ref-1 than TIMI 3. *p<0.01, TIMI 3 vs. TIMI 0-2. D. The elevated APE1/Ref-1 decreased 4 days after CAG from 1.62±0.27 ng/100 µL to 0.35±0.23 ng/100 µL. *p<0.01. APE1/Ref-1: apurinic/apyrimidinic endonuclease 1/redox effector factor 1, CAG: coronary angiograms.

Mentions: The levels of APE1/Ref-1 were higher in patients with MI than angina in the CAD group (0.81±0.101.30 for MI vs. 0.38±0.11 ng/100 µL for angina, p<0.01) (Fig. 2A). There were not significantly different between NSTEMI and STEMI (0.64±0.12 for NSTEMI vs. 0.89±0.13 ng/100 µL for STEMI, p>0.05). There were significantly higher in STEMI than in the control group, but not in NSTEMI (Fig. 2B). Also, we analyzed the levels of serum APE1/Ref-1 according to the thrombolysis in myocardial infarction (TIMI) grade flow in patients with acute coronary syndrome (ACS), including unstable angina, NSTEMI, and STEMI. The lower TIMI flow was significantly correlated with higher APE1/Ref-1 (0.12±0.07 for control vs. 0.45±0.13 for TIMI flow 3 vs. 0.88±0.09 ng/100 µL for TIMI flow 0-2, p<0.01) (Fig. 2C). Four days after the CAG, serum APE1/Ref-1 was re-measured from 37 patients who were selected randomly among the STEMI patients. The levels of the biomarker declined from 1.62±0.27 ng/100 µL to 0.35±0.23 ng/100 µL (Fig. 2D).


Elevation of the Serum Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 in Coronary Artery Disease.

Jin SA, Seo HJ, Kim SK, Lee YR, Choi S, Ahn KT, Kim JH, Park JH, Lee JH, Choi SW, Seong IW, Jeon BH, Jeong JO - Korean Circ J (2015)

Serum APE1/Ref-1 in coronary artery disease. Serum APE1/Ref-1 was assayed by ELISA. Each bar shows the mean±standard error of the mean. A. The levels of serum APE1/Ref-1 are higher in patients with myocardial infarction (MI) than angina. *p<0.01, control vs. angina and angina vs. MI, **p<0.001, control vs. MI. B. Serum APE1/Ref-1 is not significantly different between the non-ST elevation myocardial infarction (NSTEMI) and STEMI patients. *p<0.01, ns; non-specific. C. Serum APE1/Ref-1 levels are associated with thrombolysis in myocardial infarction (TIMI) grade flow in acute coronary syndrome (ACS). TIMI flow 0-2 shows higher levels of APE1/Ref-1 than TIMI 3. *p<0.01, TIMI 3 vs. TIMI 0-2. D. The elevated APE1/Ref-1 decreased 4 days after CAG from 1.62±0.27 ng/100 µL to 0.35±0.23 ng/100 µL. *p<0.01. APE1/Ref-1: apurinic/apyrimidinic endonuclease 1/redox effector factor 1, CAG: coronary angiograms.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4580694&req=5

Figure 2: Serum APE1/Ref-1 in coronary artery disease. Serum APE1/Ref-1 was assayed by ELISA. Each bar shows the mean±standard error of the mean. A. The levels of serum APE1/Ref-1 are higher in patients with myocardial infarction (MI) than angina. *p<0.01, control vs. angina and angina vs. MI, **p<0.001, control vs. MI. B. Serum APE1/Ref-1 is not significantly different between the non-ST elevation myocardial infarction (NSTEMI) and STEMI patients. *p<0.01, ns; non-specific. C. Serum APE1/Ref-1 levels are associated with thrombolysis in myocardial infarction (TIMI) grade flow in acute coronary syndrome (ACS). TIMI flow 0-2 shows higher levels of APE1/Ref-1 than TIMI 3. *p<0.01, TIMI 3 vs. TIMI 0-2. D. The elevated APE1/Ref-1 decreased 4 days after CAG from 1.62±0.27 ng/100 µL to 0.35±0.23 ng/100 µL. *p<0.01. APE1/Ref-1: apurinic/apyrimidinic endonuclease 1/redox effector factor 1, CAG: coronary angiograms.
Mentions: The levels of APE1/Ref-1 were higher in patients with MI than angina in the CAD group (0.81±0.101.30 for MI vs. 0.38±0.11 ng/100 µL for angina, p<0.01) (Fig. 2A). There were not significantly different between NSTEMI and STEMI (0.64±0.12 for NSTEMI vs. 0.89±0.13 ng/100 µL for STEMI, p>0.05). There were significantly higher in STEMI than in the control group, but not in NSTEMI (Fig. 2B). Also, we analyzed the levels of serum APE1/Ref-1 according to the thrombolysis in myocardial infarction (TIMI) grade flow in patients with acute coronary syndrome (ACS), including unstable angina, NSTEMI, and STEMI. The lower TIMI flow was significantly correlated with higher APE1/Ref-1 (0.12±0.07 for control vs. 0.45±0.13 for TIMI flow 3 vs. 0.88±0.09 ng/100 µL for TIMI flow 0-2, p<0.01) (Fig. 2C). Four days after the CAG, serum APE1/Ref-1 was re-measured from 37 patients who were selected randomly among the STEMI patients. The levels of the biomarker declined from 1.62±0.27 ng/100 µL to 0.35±0.23 ng/100 µL (Fig. 2D).

Bottom Line: Also, they revealed a negative correlation with ejection fraction (EF, r=-0.221; p=0.002).However, there were no significant differences among the three groups, were divided by their levels of APE1/Ref-1, for major adverse cardiovascular events (death, recurrent MI, stroke, revascularization) (8.2 vs. 14.0 vs. 12.5%, p=ns).They are correlated with Troponin I, NT-proBNP, and EF.

View Article: PubMed Central - PubMed

Affiliation: Divison of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.

ABSTRACT

Background and objectives: Apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1/Ref-1) is a multifunctional protein involved in the DNA base excision repair pathway, inflammation, angiogenesis, and survival pathways. We investigated serum APE1/Ref-1 in patients with coronary artery disease (CAD).

Subjects and methods: Serum APE1/Ref-1 was measured with a sandwich enzyme-linked immunosorbent assay from 360 patients who received coronary angiograms. They were divided into two groups; a control (n=57) and a CAD group (n=303), the latter included angina (n=128) and myocardial infarction (MI, n=175).

Results: The levels of APE1/Ref-1 were higher in the CAD than the control (0.63±0.07 vs. 0.12±0.07 ng/100 µL, respectively; p<0.01). They were also higher in MI than angina (0.81±0.10 vs. 0.38±0.11 ng/100 µL, respectively; p<0.01) and different according to the thrombolysis in myocardial infarction (TIMI) flow (0.88±0.09 for TIMI flow 0, 1, 2 vs. 0.45±0.13 ng/100 µL for TIMI flow 3, p<0.01) in acute coronary syndrome. In correlation analysis, the levels of APE1/Ref-1 were positively correlated with Troponin I (r=0.222; p<0.0001) and N-terminal pro-B type natriuretic peptide (NT-proBNP, r=0.217; p<0.0001) but not high sensitivity to C-reactive protein. Also, they revealed a negative correlation with ejection fraction (EF, r=-0.221; p=0.002). However, there were no significant differences among the three groups, were divided by their levels of APE1/Ref-1, for major adverse cardiovascular events (death, recurrent MI, stroke, revascularization) (8.2 vs. 14.0 vs. 12.5%, p=ns).

Conclusion: The levels of serum APE1/Ref-1 are elevated in CAD, and are higher in MI than in angina. They are correlated with Troponin I, NT-proBNP, and EF.

No MeSH data available.


Related in: MedlinePlus